FDA's OK could be start of KV's comeback

An inspection thumbs-up from the FDA last week for KV Pharma's Micro-K manufacturing ops marks a milestone in the drugmaker's GMP-violations comeback. The approval gives KV the go-ahead to produce Micro-K, a treatment for low blood potassium.

The approval follows a mid-August inspection that encompassed quality systems, manufacturing processes and facilities, all of which passed FDA muster. "The inspection was successfully completed without the issuance of a FDA 483," the drugmaker trumpets in an announcement. It expects to begin shipping Micro-K this week.

But it's still a partial comeback for KV at this point. More FDA inspections lie ahead for other products. And the outcomes of those inspections will determine whether the agency gives the go-ahead for their manufacturing and marketing.

The company's troubles date from the 2008 recalls of products made at a Missouri generics facility. The recalls were followed by the FDA's seizure of $24 million in products and its shutdown of the plant, as reported.

- here's the KV release
- see more from Reuters

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.